share_log

中國中藥：截至2023年12月31日止年度 全年業績公佈

TRAD CHI MED: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023

香港交易所 ·  Mar 21 10:46
Summary by Moomoo AI
中國中藥控股有限公司（「本公司」）公佈截至2023年12月31日止年度全年業績，營業額達人民幣181億元，較2022年同期上升26.7%；淨利潤為人民幣13.96億元，較2022年同期上升93.6%。每股基本盈利為人民幣25.52分，較去年同期上升68.1%。本集團維持穩健的財務狀況，流動資金充裕，並無重大或有負債。董事會不建議派發截至2023年12月31日止年度的末期股息。本公司股份於香港聯合交易所有限公司上市，股份代號為570。報告期內，本集團繼續加強中藥配方顆粒、中成藥、中藥飲片等業務板塊，並積極推進品牌建設及市場開拓。本集團於報告期後宣佈，國藥集團共裕有限公司提出私有化建議，並可能導致本公司股份撤銷上市地位。
中國中藥控股有限公司（「本公司」）公佈截至2023年12月31日止年度全年業績，營業額達人民幣181億元，較2022年同期上升26.7%；淨利潤為人民幣13.96億元，較2022年同期上升93.6%。每股基本盈利為人民幣25.52分，較去年同期上升68.1%。本集團維持穩健的財務狀況，流動資金充裕，並無重大或有負債。董事會不建議派發截至2023年12月31日止年度的末期股息。本公司股份於香港聯合交易所有限公司上市，股份代號為570。報告期內，本集團繼續加強中藥配方顆粒、中成藥、中藥飲片等業務板塊，並積極推進品牌建設及市場開拓。本集團於報告期後宣佈，國藥集團共裕有限公司提出私有化建議，並可能導致本公司股份撤銷上市地位。
CHINA PHARMACEUTICAL HOLDINGS LIMITED (THE “COMPANY”) ANNOUNCED ITS ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023 WITH SALES OF RMB181 BILLION, UP 26.7% OVER THE SAME PERIOD IN 2022; NET PROFIT WAS RMB13.96 BILLION, AN INCREASE OF 93.6% COMPARED TO THE SAME PERIOD IN 2022. Basic earnings per share were RMB25.52, up 68.1% from the same period last year. The Group maintains a sound financial position with ample liquidity and no significant or indebtedness. The Board of Directors does not propose the distribution of a final dividend for the year ended 31 December 2023. The company is listed on the United Stock Exchange of Hong Kong Limited with the stock code 570. During the reporting period, the Group continued to strengthen its business segments such as Chinese Medicine Formulated Granules, Chinese Medicine and Chinese Medicine Drinks, and actively promoted brand building and market exploration. The Group announced after the reporting period that Kung Yue Yue Co., Ltd., has proposed privatization, which may result in the withdrawal of the listed status of the Company's shares.
CHINA PHARMACEUTICAL HOLDINGS LIMITED (THE “COMPANY”) ANNOUNCED ITS ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023 WITH SALES OF RMB181 BILLION, UP 26.7% OVER THE SAME PERIOD IN 2022; NET PROFIT WAS RMB13.96 BILLION, AN INCREASE OF 93.6% COMPARED TO THE SAME PERIOD IN 2022. Basic earnings per share were RMB25.52, up 68.1% from the same period last year. The Group maintains a sound financial position with ample liquidity and no significant or indebtedness. The Board of Directors does not propose the distribution of a final dividend for the year ended 31 December 2023. The company is listed on the United Stock Exchange of Hong Kong Limited with the stock code 570. During the reporting period, the Group continued to strengthen its business segments such as Chinese Medicine Formulated Granules, Chinese Medicine and Chinese Medicine Drinks, and actively promoted brand building and market exploration. The Group announced after the reporting period that Kung Yue Yue Co., Ltd., has proposed privatization, which may result in the withdrawal of the listed status of the Company's shares.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more